Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Women's Health Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of The Role of Visfatin in Female Reproduction and Various Types of Gynecological Cancers

Abstract

Introduction

Visfatin is a 52-kDa protein produced mainly by adipose tissue. It is one of the cytokines known as adipokines. There is a correlation between visfatin and female reproductive health, pregnancy complications, and gynecological cancers. This mini-review summarizes the existing knowledge of the role of visfatin in female reproduction and in various types of gynecological cancers.

Methods

We performed a literature search in the PubMed database up to December 2023. We reviewed the identified articles and included those that were relevant to our objective.

Results

Visfatin has been implicated in the pathogenesis of polycystic ovary syndrome, while alterations in visfatin levels have been correlated with pregnancy complications, including gestational diabetes mellitus, acute pyelonephritis, preeclampsia, and reduced fetal growth. First trimester maternal visfatin levels are associated with infant weight. The role of visfatin has also been investigated in relation to steroidogenesis as well as breast, ovarian, and endometrial cancers. In those types of gynecological cancers, high visfatin levels were observed. Visfatin has also been detected in the follicular fluid, and it has been correlated with the number of retrieved oocytes in fertilization.

Conclusion

The results from published studies are contradictory because visfatin levels vary across conditions due to its complex mode of action. Visfatin could potentially serve as a prognostic biomarker in various reproductive conditions and as a therapeutic target in various types of gynecological cancers. Additional studies are needed to clarify visfatin’s role in female reproduction because its effects can vary depending on the tissue in which it is present.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cwhr/10.2174/0115734048343364250303044156
2025-03-06
2025-04-21

  • From This Site

    /content/journals/cwhr/10.2174/0115734048343364250303044156
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Koerner A. Kratzsch J. Kiess W. Adipocytokines: Leptin—the classical, resistin—the controversical, adiponectin—the promising, and more to come. Best Pract. Res. Clin. Endocrinol. Metab. 2005 19 4 525 546 10.1016/j.beem.2005.07.008 16311215
    [Google Scholar]
  2. Shen C.J. Tsai E.M. Lee J.N. Chen Y.L. Lee C.H. Chan T.F. The concentrations of visfatin in the follicular fluids of women undergoing controlled ovarian stimulation are correlated to the number of oocytes retrieved. Fertil. Steril. 2010 93 6 1844 1850 10.1016/j.fertnstert.2008.12.090 19200966
    [Google Scholar]
  3. Hug C. Lodish H.F. Medicine. Visfatin: A new adipokine. Science 2005 307 5708 366 367 10.1126/science.1106933 15604359
    [Google Scholar]
  4. Samal B. Sun Y. Stearns G. Xie C. Suggs S. McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 1994 14 2 1431 1437 8289818
    [Google Scholar]
  5. Ognjanovic S. Bryant-Greenwood G.D. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am. J. Obstet. Gynecol. 2002 187 4 1051 1058 10.1067/mob.2002.126295 12389004
    [Google Scholar]
  6. Kendal C.E. Bryant-Greenwood G.D. Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells. Placenta 2007 28 4 305 314 10.1016/j.placenta.2006.03.011 16701870
    [Google Scholar]
  7. Curat C.A. Wegner V. Sengenès C. Miranville A. Tonus C. Busse R. Bouloumié A. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006 49 4 744 747 10.1007/s00125‑006‑0173‑z 16496121
    [Google Scholar]
  8. Stępień S. Olczyk P. Gola J. Komosińska-Vassev K. Mielczarek-Palacz A. The role of selected adipocytokines in ovarian cancer and endometrial cancer. Cells 2023 12 8 1118 10.3390/cells12081118 37190027
    [Google Scholar]
  9. Dakroub A. A Nasser S. Younis N. Bhagani H. Al-Dhaheri Y. Pintus G. Eid A.A. El-Yazbi A.F. Eid A.H. Visfatin: A possible role in cardiovasculo-metabolic disorders. Cells 2020 9 11 2444 10.3390/cells9112444 33182523
    [Google Scholar]
  10. Luk T. Malam Z. Marshall J.C. Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. J. Leukoc. Biol. 2008 83 4 804 816 10.1189/jlb.0807581 18252866
    [Google Scholar]
  11. Araki S. Dobashi K. Kubo K. Kawagoe R. Yamamoto Y. Kawada Y. Asayama K. Shirahata A. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity 2008 16 2 384 388 10.1038/oby.2007.54 18239648
    [Google Scholar]
  12. Zahorska-Markiewicz B. Olszanecka-Glinianowicz M. Janowska J. Kocełak P. Semik-Grabarczyk E. Holecki M. Dąbrowski P. Skorupa A. Serum concentration of visfatin in obese women. Metabolism 2007 56 8 1131 1134 10.1016/j.metabol.2007.04.007 17618961
    [Google Scholar]
  13. Haider D.G. Schaller G. Kapiotis S. Maier C. Luger A. Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006 49 8 1909 1914 10.1007/s00125‑006‑0303‑7 16736128
    [Google Scholar]
  14. Chen M.P. Chung F.M. Chang D.M. Tsai J.C.R. Huang H.F. Shin S.J. Lee Y.J. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2006 91 1 295 299 10.1210/jc.2005‑1475 16234302
    [Google Scholar]
  15. Tilg H. Moschen A.R. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006 6 10 772 783 10.1038/nri1937 16998510
    [Google Scholar]
  16. Dahl T.B. Yndestad A. Skjelland M. Øie E. Dahl A. Michelsen A. Damås J.K. Tunheim S.H. Ueland T. Smith C. Bendz B. Tonstad S. Gullestad L. Frøland S.S. Krohg-Sørensen K. Russell D. Aukrust P. Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007 115 8 972 980 10.1161/CIRCULATIONAHA.106.665893 17283255
    [Google Scholar]
  17. Ismaiel A. Leucuta D.C. Popa S.L. Dumitrascu D.L. Serum visfatin levels in nonalcoholic fatty liver disease and liver fibrosis: Systematic review and meta-analysis. J. Clin. Med. 2021 10 14 3029 10.3390/jcm10143029 34300193
    [Google Scholar]
  18. Han D.F. Li Y. Xu H.Y. Li R.H. Zhao D. An update on the emerging role of visfatin in the pathogenesis of osteoarthritis and pharmacological intervention. Evid. Based Complement. Alternat. Med. 2020 2020 1 8303570 10.1155/2020/8303570 32831881
    [Google Scholar]
  19. Chan T.F. Chen Y.L. Lee C.H. Chou F.H. Wu L.C. Jong S.B. Tsai E.M. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J. Soc. Gynecol. Investig. 2006 13 5 364 367 10.1016/j.jsgi.2006.04.007 16814166
    [Google Scholar]
  20. Haider D.G. Handisurya A. Storka A. Vojtassakova E. Luger A. Pacini G. Tura A. Wolzt M. Kautzky-Willer A. Visfatin response to glucose is reduced in women with gestational diabetes mellitus. Diabetes Care 2007 30 7 1889 1891 10.2337/dc07‑0013 17416788
    [Google Scholar]
  21. Akturk M. Altinova A.E. Mert I. Buyukkagnici U. Sargin A. Arslan M. Danisman N. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J. Endocrinol. Invest. 2008 31 7 610 613 10.1007/BF03345611 18787378
    [Google Scholar]
  22. Rezvan N. Hosseinzadeh-Attar M.J. Masoudkabir F. Moini A. Janani L. Mazaherioun M. Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy. Arch. Gynecol. Obstet. 2012 285 5 1257 1262 10.1007/s00404‑011‑2156‑7 22167446
    [Google Scholar]
  23. Lewandowski K.C. Stojanovic N. Press M. Tuck S.M. Szosland K. Bienkiewicz M. Vatish M. Lewinski A. Prelevic G.M. Randeva H.S. Elevated serum levels of visfatin in gestational diabetes: A comparative study across various degrees of glucose tolerance. Diabetologia 2007 50 5 1033 1037 10.1007/s00125‑007‑0610‑7 17334748
    [Google Scholar]
  24. Krzyzanowska K. Krugluger W. Mittermayer F. Rahman R. Haider D. Shnawa N. Schernthaner G. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin. Sci. 2006 110 5 605 609 10.1042/CS20050363 16489932
    [Google Scholar]
  25. Ma Y. Cheng Y. Wang J. Cheng H. Zhou S. Li X. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes Res. Clin. Pract. 2010 90 1 60 65 10.1016/j.diabres.2010.06.010 20621376
    [Google Scholar]
  26. Coskun A. Ozkaya M. Kiran G. Kilinc M. Arikan D.C. Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus. J. Matern. Fetal Neonatal Med. 2010 23 9 1014 1018 10.3109/14767050903551426 20059442
    [Google Scholar]
  27. Mazaki-Tovi S. Vaisbuch E. Romero R. Kusanovic J.P. Chaiworapongsa T. Kim S.K. Nhan-Chang C.L. Gomez R. Yoon B.H. Yeo L. Mittal P. Ogge G. Gonzalez J.M. Hassan S.S. Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis. Am. J. Reprod. Immunol. 2010 63 3 252 262 10.1111/j.1600‑0897.2009.00804.x 20085562
    [Google Scholar]
  28. Fasshauer M. Waldeyer T. Seeger J. Schrey S. Ebert T. Kratzsch J. Lossner U. Bluher M. Stumvoll M. Faber R. Stepan H. Serum levels of the adipokine visfatin are increased in pre‐eclampsia. Clin. Endocrinol. 2008 69 1 69 73 10.1111/j.1365‑2265.2007.03147.x 18034779
    [Google Scholar]
  29. Adali E. Yildizhan R. Kolusari A. Kurdoglu M. Bugdayci G. Sahin H.G. Kamaci M. Increased visfatin and leptin in pregnancies complicated by pre-eclampsia. J. Matern. Fetal Neonatal Med. 2009 22 10 873 879 10.1080/14767050902994622 19488934
    [Google Scholar]
  30. Zorba E. Vavilis D. Venetis C.A. Zournatzi V. Kellartzis D. Tarlatzis B.C. Visfatin serum levels are increased in women with preeclampsia: A case-control study. J. Matern. Fetal Neonatal Med. 2012 25 9 1668 1673 10.3109/14767058.2012.657275 22272940
    [Google Scholar]
  31. Hu W. Wang Z. Wang H. Huang H. Dong M. Serum visfatin levels in late pregnancy and pre‐eclampsia. Acta Obstet. Gynecol. Scand. 2008 87 4 413 418 10.1080/00016340801976012 18382866
    [Google Scholar]
  32. Kim S.C. Park M.J. Joo B.S. Joo J.K. Suh D.S. Lee K.S. Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia. J. Obstet. Gynaecol. Res. 2012 38 4 665 673 10.1111/j.1447‑0756.2011.01773.x 22380724
    [Google Scholar]
  33. Malamitsi-Puchner A. Briana D.D. Boutsikou M. Kouskouni E. Hassiakos D. Gourgiotis D. Perinatal circulating visfatin levels in intrauterine growth restriction. Pediatrics 2007 119 6 e1314 e1318 10.1542/peds.2006‑2589 17502346
    [Google Scholar]
  34. Valsamakis G. Papatheodorou D.C. Margeli A. Bakoulas V. Kapantais E. Papassotiriou I. Creatsas G. Kumar S. Mastorakos G. First trimester maternal BMI is a positive predictor of cord blood c-peptide levels while maternal visfatin levels is a negative predictor of birth weight. Hormones 2014 13 1 87 94 10.1007/BF03401324 24722131
    [Google Scholar]
  35. Goodarzi M.O. Dumesic D.A. Chazenbalk G. Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat. Rev. Endocrinol. 2011 7 4 219 231 10.1038/nrendo.2010.217 21263450
    [Google Scholar]
  36. Chen X. Jia X. Qiao J. Guan Y. Kang J. Adipokines in reproductive function: A link between obesity and polycystic ovary syndrome. J. Mol. Endocrinol. 2013 50 2 R21 R37 10.1530/JME‑12‑0247 23335807
    [Google Scholar]
  37. Tay C.T. Garrad R. Mousa A. Bahri M. Joham A. Teede H. Polycystic ovary syndrome (PCOS): International collaboration to translate evidence and guide future research. J. Endocrinol. 2023 257 3 e220232 36946556
    [Google Scholar]
  38. Bozdag G. Mumusoglu S. Zengin D. Karabulut E. Yildiz B.O. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. 2016 31 12 2841 2855 10.1093/humrep/dew218 27664216
    [Google Scholar]
  39. Matalliotakis I. Kourtis A. Koukoura O. Panidis D. Polycystic ovary syndrome: Etiology and pathogenesis. Arch. Gynecol. Obstet. 2006 274 4 187 197 10.1007/s00404‑006‑0171‑x 16685527
    [Google Scholar]
  40. Ehrmann D.A. Polycystic ovary syndrome. N. Engl. J. Med. 2005 352 12 1223 1236 10.1056/NEJMra041536 15788499
    [Google Scholar]
  41. Legato M.J. Gender-specific aspects of obesity. Int. J. Fertil. Womens Med. 1997 42 3 184 197 9222803
    [Google Scholar]
  42. Björntorp P. Abdominal obesity and the metabolic syndrome. Ann. Med. 1992 24 6 465 468 10.3109/07853899209166997 1485940
    [Google Scholar]
  43. Tan B.K. Chen J. Digby J.E. Keay S.D. Kennedy C.R. Randeva H.S. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: Parallel increase in plasma visfatin. J. Clin. Endocrinol. Metab. 2006 91 12 5022 5028 10.1210/jc.2006‑0936 17003086
    [Google Scholar]
  44. Chan T.F. Chen Y.L. Chen H.H. Lee C.H. Jong S.B. Tsai E.M. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil. Steril. 2007 88 2 401 405 10.1016/j.fertnstert.2006.11.120 17335820
    [Google Scholar]
  45. Kowalska I. Straczkowski M. Nikolajuk A. Adamska A. Karczewska-Kupczewska M. Otziomek E. Wolczynski S. Gorska M. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum. Reprod. 2007 22 7 1824 1829 10.1093/humrep/dem118 17582143
    [Google Scholar]
  46. Panidis D. Farmakiotis D. Rousso D. Katsikis I. Delkos D. Piouka A. Gerou S. Diamanti-Kandarakis E. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur. J. Intern. Med. 2008 19 6 406 412 10.1016/j.ejim.2007.05.014 18848173
    [Google Scholar]
  47. Carmina E. Bucchieri S. Mansueto P. Rini G. Ferin M. Lobo R.A. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil. Steril. 2009 91 4 Suppl. 1332 1335 10.1016/j.fertnstert.2008.03.007 18455165
    [Google Scholar]
  48. Ozkaya M. Cakal E. Ustun Y. Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil. Steril. 2010 93 3 880 884 10.1016/j.fertnstert.2008.10.058 19111298
    [Google Scholar]
  49. Plati E. Kouskouni E. Malamitsi-Puchner A. Boutsikou M. Kaparos G. Baka S. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil. Steril. 2010 94 4 1451 1456 10.1016/j.fertnstert.2009.04.055 19523615
    [Google Scholar]
  50. Seow K.M. Hwang J.L. Wang P.H. Ho L.T. Juan C.C. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum. Reprod. 2011 26 10 2869 2873 10.1093/humrep/der267 21840905
    [Google Scholar]
  51. Tsouma I. Kouskouni E. Demeridou S. Boutsikou M. Hassiakos D. Chasiakou A. Hassiakou S. Gennimata V. Baka S. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: Influence of adipocytokines levels. In Vivo 2014 28 5 935 939 25189910
    [Google Scholar]
  52. Spanos N. Tziomalos K. Macut D. Koiou E. Kandaraki E.A. Delkos D. Tsourdi E. Panidis D. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: Cross-sectional correlations and the effects of weight loss. Obes. Facts 2012 5 4 495 504 10.1159/000341579 22854419
    [Google Scholar]
  53. Sethi J.K. Vidal-Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes? Trends Mol. Med. 2005 11 8 344 347 10.1016/j.molmed.2005.06.010 16005682
    [Google Scholar]
  54. Sun Y. Wu Z. Wei L. Liu C. Zhu S. Tang S. High-visfatin levels in women with polycystic ovary syndrome: Evidence from a meta-analysis. Gynecol. Endocrinol. 2015 31 10 808 814 10.3109/09513590.2015.1056140 26422683
    [Google Scholar]
  55. Güdücü N. İşçi H. Görmüş U. Yiğiter A.B. Dünder I. Serum visfatin levels in women with polycystic ovary syndrome. Gynecol. Endocrinol. 2012 28 8 619 623 10.3109/09513590.2011.650749 22313145
    [Google Scholar]
  56. Olszanecka-Glinianowicz M. Madej P. Zdun D. Bożentowicz-Wikarek M. Sikora J. Chudek J. Skałba P. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur. J. Obstet. Gynecol. Reprod. Biol. 2012 162 1 55 61 10.1016/j.ejogrb.2012.01.026 22397743
    [Google Scholar]
  57. Panidis D. Farmakiotis D. Rousso D. Katsikis I. Kourtis A. Diamanti-Kandarakis E. Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil. Steril. 2005 84 2 538 540 10.1016/j.fertnstert.2005.02.017 16084906
    [Google Scholar]
  58. Diamanti-Kandarakis E. Bartzis M.I. Zapanti E.D. Spina G.G. Filandra F.A. Tsianateli T.C. Bergiele A.T. Kouli C.R. Polymorphism T→C (−34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil. Steril. 1999 71 3 431 435 10.1016/S0015‑0282(98)00512‑3 10065777
    [Google Scholar]
  59. Nestler J. Powers L.P. Matt D.W. Steingold K.A. Plymate S.R. Rittmaster R.S. Clore J.N. Blackard W.G. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1991 72 1 83 89 10.1210/jcem‑72‑1‑83 1898744
    [Google Scholar]
  60. Chang Y.C. Chang T.J. Lee W.J. Chuang L.M. The relationship of visfatin/pre–B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010 59 1 93 99 10.1016/j.metabol.2009.07.011 19765775
    [Google Scholar]
  61. Steiner C.A. Janez A. Jensterle M. Reisinger K. Forst T. Pfützner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J. Diabetes Sci. Technol. 2007 1 2 211 217 10.1177/193229680700100212 19888409
    [Google Scholar]
  62. Chen J. Hu L. Ling Y. Xu Y. Yu X. Ma L. Shou M. Risk correlation analysis between polycystic ovary syndrome (PCOS) and serum visfatin levels in middle-aged women: Systematic review and meta-analysis. Discov. Med. 2023 35 175 168 177 10.24976/Discov.Med.202335175.17 37105926
    [Google Scholar]
  63. Bannigida D.M. Nayak S.B. R V. Serum visfatin and adiponectin – Markers in women with polycystic ovarian syndrome. Arch. Physiol. Biochem. 2020 126 4 283 286 10.1080/13813455.2018.1518987 30318936
    [Google Scholar]
  64. Ali A.I. Nori W. Correlation of serum visfatin level in non-obese women with polycystic ovary syndrome and matched control. Reprod. Sci. 2022 29 11 3285 3293 10.1007/s43032‑022‑00986‑z 35687303
    [Google Scholar]
  65. Duley L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 2009 33 3 130 137 10.1053/j.semperi.2009.02.010 19464502
    [Google Scholar]
  66. Steegers E.A.P. von Dadelszen P. Duvekot J.J. Pijnenborg R. Pre-eclampsia. Lancet 2010 376 9741 631 644 10.1016/S0140‑6736(10)60279‑6 20598363
    [Google Scholar]
  67. Lyall F. The human placental bed revisited. Placenta 2002 23 8-9 555 562 10.1053/plac.2002.0850 12361674
    [Google Scholar]
  68. Kim Y.M. Bujold E. Chaiworapongsa T. Gomez R. Yoon B.H. Thaler H.T. Rotmensch S. Romero R. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am. J. Obstet. Gynecol. 2003 189 4 1063 1069 10.1067/S0002‑9378(03)00838‑X 14586356
    [Google Scholar]
  69. Ives C.W. Sinkey R. Rajapreyar I. Tita A.T.N. Oparil S. Preeclampsia—pathophysiology and clinical presentations. J. Am. Coll. Cardiol. 2020 76 14 1690 1702 10.1016/j.jacc.2020.08.014 33004135
    [Google Scholar]
  70. Haugen F. Ranheim T. Harsem N.K. Lips E. Staff A.C. Drevon C.A. Increased plasma levels of adipokines in preeclampsia: Relationship to placenta and adipose tissue gene expression. Am. J. Physiol. Endocrinol. Metab. 2006 290 2 E326 E333 10.1152/ajpendo.00020.2005 16144822
    [Google Scholar]
  71. Cortelazzi D. Corbetta S. Ronzoni S. Pelle F. Marconi A. Cozzi V. Cetin I. Cortelazzi R. Beck-Peccoz P. Spada A. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin. Endocrinol. 2007 66 3 447 453 10.1111/j.1365‑2265.2007.02761.x 17302882
    [Google Scholar]
  72. Mazaki-Tovi S. Romero R. Kim S.K. Vaisbuch E. Kusanovic J.P. Erez O. Chaiworapongsa T. Gotsch F. Mittal P. Nhan-Chang C.L. Than N.G. Gomez R. Nien J.K. Edwin S.S. Pacora P. Yeo L. Hassan S.S. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J. Matern. Fetal Neonatal Med. 2010 23 8 857 868 10.3109/14767050903301017 19900033
    [Google Scholar]
  73. Mazaki-Tovi S. Vaisbuch E. Romero R. Kusanovic J.P. Chaiworapongsa T. Kim S.K. Nhan-Chang C.L. Gomez R. Alpay Savasan Z. Madan I. Yoon B.H. Yeo L. Mittal P. Ogge G. Gonzalez J.M. Hassan S.S. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J. Matern. Fetal Neonatal Med. 2010 23 10 1119 1128 10.3109/14767050903572190 20121389
    [Google Scholar]
  74. Bawah A.T. Yeboah F.A. Nanga S. Alidu H. Ngala R.A. Serum adipocytokines and adiposity as predictive indices of preeclampsia. Clin. Hypertens. 2020 26 1 19 10.1186/s40885‑020‑00152‑0 33014422
    [Google Scholar]
  75. Amiri-Dashatan N. Koushki M. Hosseini H. Khodabandehloo H. Fathi M. Doustimotlagh A.H. Rezaei-Tavirani M. Association between circulating visfatin and pre-eclampsia: A systematic review and meta-analysis. J. Matern. Fetal Neonatal Med. 2022 35 13 2606 2618 10.1080/14767058.2020.1789581 32635792
    [Google Scholar]
  76. Malamitsi-Puchner A. Briana D.D. Gourgiotis D. Boutsikou M. Baka S. Hassiakos D. Blood visfatin concentrations in normal full‐term pregnancies. Acta Paediatr. 2007 96 4 526 529 10.1111/j.1651‑2227.2007.00231.x 17391471
    [Google Scholar]
  77. Briana D.D. Malamitsi-Puchner A. The role of adipocytokines in fetal growth. Ann. N. Y. Acad. Sci. 2010 1205 1 82 87 10.1111/j.1749‑6632.2010.05650.x 20840257
    [Google Scholar]
  78. Gluckman P.D. Hanson M.A. Pinal C. The developmental origins of adult disease. Matern. Child Nutr. 2005 1 3 130 141 10.1111/j.1740‑8709.2005.00020.x 16881892
    [Google Scholar]
  79. Kiess W. Petzold S. Töpfer M. Garten A. Blüher S. Kapellen T. Körner A. Kratzsch J. Adipocytes and adipose tissue. Best Pract. Res. Clin. Endocrinol. Metab. 2008 22 1 135 153 10.1016/j.beem.2007.10.002 18279785
    [Google Scholar]
  80. Briana D.D. Boutsikou M. Gourgiotis D. Kontara L. Baka S. Iacovidou N. Hassiakos D. Malamitsi-Puchner A. Role of visfatin, insulin-like growth factor-I and insulin in fetal growth. J. Perinat. Med. 2007 35 4 326 329 10.1515/JPM.2007.071 17511597
    [Google Scholar]
  81. Nasri K. Mehrabi M. Bayani M. Almasi-Hashiani A. Maternal saliva visfatin level in term and preterm labor: A case control study. PLoS One 2023 18 7 e0288786 10.1371/journal.pone.0288786 37459321
    [Google Scholar]
  82. Hill J.B. Sheffield J.S. McIntire D.D. Wendel G.D. Jr Acute pyelonephritis in pregnancy. Obstet. Gynecol. 2005 105 1 18 23 10.1097/01.AOG.0000149154.96285.a0 15625136
    [Google Scholar]
  83. Foxman B. Klemstine K.L. Brown P.D. Acute pyelonephritis in US hospitals in 1997: Hospitalization and in-hospital mortality. Ann. Epidemiol. 2003 13 2 144 150 10.1016/S1047‑2797(02)00272‑7 12559674
    [Google Scholar]
  84. Gilstrap L.C. III Cunningham F.G. Whalley P.J. Acute pyelonephritis in pregnancy: An anterospective study. Obstet. Gynecol. 1981 57 4 409 413 7243084
    [Google Scholar]
  85. Gurman G. Schlaeffer F. Kopernic G. Adult respiratory distress syndrome as a complication of acute pyelonephritis during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 1990 36 1-2 75 80 10.1016/0028‑2243(90)90052‑3 2194868
    [Google Scholar]
  86. Cole D.E. Taylor T.L. McCullough D.M. Shoff C.T. Derdak S. Acute respiratory distress syndrome in pregnancy. Crit. Care Med. 2005 33 10 Suppl. S269 S278 10.1097/01.CCM.0000182478.14181.DA 16215347
    [Google Scholar]
  87. Mabie W. Barton J.R. Sibai B. Septic shock in pregnancy. Obstet. Gynecol. 1997 90 4 553 561 10.1016/S0029‑7844(97)00352‑9 9380315
    [Google Scholar]
  88. Sheffield J.S. Sepsis and septic shock in pregnancy. Crit. Care Clin. 2004 20 4 651 660, viii 10.1016/j.ccc.2004.05.012 15388194
    [Google Scholar]
  89. Kusanovic J.P. Romero R. Espinoza J. Gotsch F. Edwin S. Chaiworapongsa T. Mittal P. Soto E. Erez O. Mazaki-Tovi S. Than N.G. Friel L.A. Yoon B.H. Mazor M. Hassan S.S. Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis. J. Matern. Fetal Neonatal Med. 2007 20 11 803 811 10.1080/14767050701492851 17853184
    [Google Scholar]
  90. Chaiworapongsa T. Romero R. Gotsch F. Kusanovic J.P. Mittal P. Kim S.K. Erez O. Vaisbuch E. Mazaki-Tovi S. Kim C.J. Dong Z. Yeo L. Hassan S.S. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J. Matern. Fetal Neonatal Med. 2010 23 2 167 178 10.3109/14767050903067378 20213923
    [Google Scholar]
  91. Gotsch F. Romero R. Espinoza J. Kusanovic J.P. Mazaki-Tovi S. Erez O. Than N.G. Edwin S. Mazor M. Yoon B.H. Hassan S.S. Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy. J. Matern. Fetal Neonatal Med. 2007 20 10 735 744 10.1080/14767050701511650 17763275
    [Google Scholar]
  92. Nien J.K. Romero R. Hoppensteadt D. Erez O. Espinoza J. Soto E. Kusanovic J.P. Gotsch F. Kim C.J. Mittal P. Fareed J. Santolaya J. Chaiworapongsa T. Edwin S. Pineles B. Hassan S. Pyelonephritis during pregnancy: A cause for an acquired deficiency of protein Z. J. Matern. Fetal Neonatal Med. 2008 21 9 629 637 10.1080/14767050802214659 18828054
    [Google Scholar]
  93. Soto E. Richani K. Romero R. Espinoza J. Chaiworapongsa T. Nien J.K. Edwin S. Kim Y.M. Hong J.S. Goncalves L. Mazor M. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy. J. Matern. Fetal Neonatal Med. 2005 17 4 247 252 10.1080/14767050500072805 16147833
    [Google Scholar]
  94. Mazaki-Tovi S. Romero R. Kusanovic J.P. Erez O. Gotsch F. Mittal P. Than N.G. Nhan-Chang C.L. Hamill N. Vaisbuch E. Chaiworapongsa T. Edwin S.S. Nien J.K. Gomez R. Espinoza J. Kendal-Wright C. Hassan S.S. Bryant-Greenwood G. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: An association with subclinical intrauterine infection in preterm parturition. J. Perinat. Med. 2008 36 6 485 496 10.1515/JPM.2008.084 18598235
    [Google Scholar]
  95. Metzger B.E. Coustan D.R. The Organizing Committee Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 1998 21 Suppl. 2 B161 B167 9704245
    [Google Scholar]
  96. Dabelea D. Snell-Bergeon J.K. Hartsfield C.L. Bischoff K.J. Hamman R.F. McDuffie R.S. Kaiser Permanente of Colorado GDM Screening Program Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser permanente of colorado GDM screening program. Diabetes Care 2005 28 3 579 584 10.2337/diacare.28.3.579 15735191
    [Google Scholar]
  97. Tsiotra P.C. Halvatsiotis P. Patsouras K. Maratou E. Salamalekis G. Raptis S.A. Dimitriadis G. Boutati E. Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus. Peptides 2018 101 157 166 10.1016/j.peptides.2018.01.005 29337272
    [Google Scholar]
  98. Bawah A.T. Seini M.M. Abaka-Yawason A. Alidu H. Nanga S. Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus. Lipids Health Dis. 2019 18 1 221 10.1186/s12944‑019‑1169‑2 31836012
    [Google Scholar]
  99. Souvannavong-Vilivong X. Sitticharoon C. Klinjampa R. Keadkraichaiwat I. Sripong C. Chatree S. Sririwichitchai R. Lertbunnaphong T. Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM. Acta Diabetol. 2019 56 10 1121 1131 10.1007/s00592‑019‑01355‑0 31076892
    [Google Scholar]
  100. Ferreira A.F.A. Rezende J.C. Vaikousi E. Akolekar R. Nicolaides K.H. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin. Chem. 2011 57 4 609 613 10.1373/clinchem.2010.159806 21325104
    [Google Scholar]
  101. Telejko B. Kuzmicki M. Zonenberg A. Szamatowicz J. Wawrusiewicz-Kurylonek N. Nikolajuk A. Kretowski A. Gorska M. Visfatin in gestational diabetes: Serum level and mRNA expression in fat and placental tissue. Diabetes Res. Clin. Pract. 2009 84 1 68 75 10.1016/j.diabres.2008.12.017 19185944
    [Google Scholar]
  102. Morgan S.A. Bringolf J.B. Seidel E.R. Visfatin expression is elevated in normal human pregnancy. Peptides 2008 29 8 1382 1389 10.1016/j.peptides.2008.04.010 18524416
    [Google Scholar]
  103. Zhaoxia L. Ying W. Danqing C. Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus. Diabetes Res. Clin. Pract. 2012 96 3 e76 e79 10.1016/j.diabres.2012.02.020 22446095
    [Google Scholar]
  104. Lee Y.C. Yang Y.H. Su J.H. Chang H.L. Hou M.F. Yuan S.S.F. High visfatin expression in breast cancer tissue is associated with poor survival. Cancer Epidemiol. Biomarkers Prev. 2011 20 9 1892 1901 10.1158/1055‑9965.EPI‑11‑0399 21784959
    [Google Scholar]
  105. Begum P. Richardson C.E. Carmichael A.R. Obesity in post menopausal women with a family history of breast cancer: Prevalence and risk awareness. Int. Semin. Surg. Oncol. 2009 6 1 1 10.1186/1477‑7800‑6‑1 19133122
    [Google Scholar]
  106. Hou W. Xu Y. Yu T. Zhang L. Zhang W. Fu C. Sun Y. Wu Q. Chen L. Adipocytokines and breast cancer risk. Chin. Med. J. 2007 120 18 1592 1596 10.1097/00029330‑200709020‑00009 17908478
    [Google Scholar]
  107. Brown A. Raynor P. Lee M. Young mothers who choose to breast feed: The importance of being part of a supportive breast-feeding community. Midwifery 2011 27 1 53 59 10.1016/j.midw.2009.09.004 19896254
    [Google Scholar]
  108. Koike Folgueira M.A.A. Carraro D.M. Brentani H. da Costa Patrão D.F. Barbosa E.M. Netto M.M. Caldeira J.R.F. Katayama M.L.H. Soares F.A. Oliveira C.T. Reis L.F.L. Kaiano J.H.L. Camargo L.P. Vêncio R.Z.N. Snitcovsky I.M.L. Makdissi F.B.A. da Silva e Silva P.J. Góes J.C.G.S. Brentani M.M. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 2005 11 20 7434 7443 10.1158/1078‑0432.CCR‑04‑0548 16243817
    [Google Scholar]
  109. Bae S.K. Kim S.R. Kim J.G. Kim J.Y. Koo T.H. Jang H.O. Yun I. Yoo M.A. Bae M.K. Hypoxic induction of human visfatin gene is directly mediated by hypoxia‐inducible factor‐1. FEBS Lett. 2006 580 17 4105 4113 10.1016/j.febslet.2006.06.052 16828081
    [Google Scholar]
  110. Yonezawa T. Haga S. Kobayashi Y. Takahashi T. Obara Y. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway. FEBS Lett. 2006 580 28-29 6635 6643 10.1016/j.febslet.2006.11.014 17123517
    [Google Scholar]
  111. Wang Y.Y. Hung A.C. Lo S. Yuan S.S.F. Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential. Cancer Lett. 2021 498 229 239 10.1016/j.canlet.2020.10.045 33152400
    [Google Scholar]
  112. Ghaneialvar H. Shiri S. Kenarkoohi A. Fallah Vastani Z. Ahmadi A. Khorshidi A. Khooz R. Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis. Health Sci. Rep. 2022 5 6 e895 10.1002/hsr2.895 36415563
    [Google Scholar]
  113. Shackelford R.E. Bui M.M. Coppola D. Hakam A. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int. J. Clin. Exp. Pathol. 2010 3 5 522 527 20606733
    [Google Scholar]
  114. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  115. Makker V. MacKay H. Ray-Coquard I. Levine D.A. Westin S.N. Aoki D. Oaknin A. Endometrial cancer. Nat. Rev. Dis. Primers 2021 7 1 88 10.1038/s41572‑021‑00324‑8 34887451
    [Google Scholar]
  116. Terzic M. Aimagambetova G. Kunz J. Bapayeva G. Aitbayeva B. Terzic S. Laganà A.S. Molecular basis of endometriosis and endometrial cancer: Current knowledge and future perspectives. Int. J. Mol. Sci. 2021 22 17 9274 10.3390/ijms22179274 34502183
    [Google Scholar]
  117. Yen T.T. Wang T.L. Fader A.N. Shih I.M. Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. Int. J. Gynecol. Pathol. 2020 39 1 26 35 10.1097/PGP.0000000000000585 30741844
    [Google Scholar]
  118. Trojano G. Olivieri C. Tinelli R. Damiani G.R. Pellegrino A. Cicinelli E. Conservative treatment in early stage endometrial cancer: A review. Acta Biomed. 2019 90 4 405 410 31910163
    [Google Scholar]
  119. Ding S. Madu C.O. Lu Y. The impact of hormonal imbalances associated with obesity on the incidence of endometrial cancer in postmenopausal women. J. Cancer 2020 11 18 5456 5465 10.7150/jca.47580 32742493
    [Google Scholar]
  120. Wang Y. Gao C. Zhang Y. Gao J. Teng F. Tian W. Yang W. Yan Y. Xue F. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways. Gynecol. Oncol. 2016 143 1 168 178 10.1016/j.ygyno.2016.07.109 27473926
    [Google Scholar]
  121. Cymbaluk-Płoska A. Chudecka-Głaz A. Pius-Sadowska E. Sompolska-Rzechuła A. Machaliński B. Menkiszak J. Circulating serum level of visfatin in patients with endometrial cancer. BioMed Res. Int. 2018 2018 1 1 9 10.1155/2018/8576179 29516012
    [Google Scholar]
  122. Luhn P. Dallal C.M. Weiss J.M. Black A. Huang W.Y. Lacey J.V. Jr Hayes R.B. Stanczyk F.Z. Wentzensen N. Brinton L.A. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 2013 22 7 1304 1312 10.1158/1055‑9965.EPI‑13‑0258 23696194
    [Google Scholar]
  123. Ilhan T.T. Kebapcilar A. Yilmaz S.A. Ilhan T. Kerimoglu O.S. Pekin A.T. Akyurek F. Unlu A. Celik C. Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis. Asian Pac. J. Cancer Prev. 2015 16 11 4503 4508 10.7314/APJCP.2015.16.11.4503 26107194
    [Google Scholar]
  124. Ray I. Meira L.B. Michael A. Ellis P.E. Adipocytokines and disease progression in endometrial cancer: A systematic review. Cancer Metastasis Rev. 2022 41 1 211 242 10.1007/s10555‑021‑10002‑6 34951691
    [Google Scholar]
  125. Michalczyk K. Niklas N. Rychlicka M. Cymbaluk-Płoska A. The influence of biologically active substances secreted by the adipose tissue on endometrial cancer. Diagnostics 2021 11 3 494 10.3390/diagnostics11030494 33799622
    [Google Scholar]
  126. Reverchon M. Cornuau M. Cloix L. Ramé C. Guerif F. Royère D. Dupont J. Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis. Mol. Hum. Reprod. 2013 19 5 313 326 10.1093/molehr/gat002 23315983
    [Google Scholar]
  127. Zhou J. Seidel E.R. Estrogens induce visfatin expression in 3T3-L1 cells. Peptides 2010 31 2 271 274 10.1016/j.peptides.2009.12.004 20004694
    [Google Scholar]
  128. Tsouma I. Kouskouni E. Demeridou S. Boutsikou M. Hassiakos D. Chasiakou A. Hassiakou S. Baka S. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecol. Endocrinol. 2014 30 7 516 519 10.3109/09513590.2014.896896 24576225
    [Google Scholar]
  129. Fiedler K. Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod. Biol. Endocrinol. 2012 10 1 32 10.1186/1477‑7827‑10‑32 22531097
    [Google Scholar]
/content/journals/cwhr/10.2174/0115734048343364250303044156
Loading
The Role of Visfatin in Female Reproduction and Various Types of Gynecological Cancers
Bentham Science Publishers ; https://doi.org/10.2174/0115734048343364250303044156
/content/journals/cwhr/10.2174/0115734048343364250303044156
/content/journals/cwhr/10.2174/0115734048343364250303044156
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Adipokines ; visfatin ; obesity ; reproduction ; adipose tissue ; insulin resistance ; PCOS ; preeclampsia

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test